Delivery of the Bioactive Component Paeonol by Dual pH‐Responsive Nanoparticles Enhances Anti‐Metastatic Tumor Efficiency
Source abstract
Abstract
Abstract In spite of several treatments involving chemotherapy, immunotherapy, and molecularly targeted agents, patients with metastatic breast cancers (MBCs) usually have a poor prognosis due to the toxic side effects, poor selectivity, and drug resistance of these treatments. Thus, new effective treatments with reduced side effects are needed. Paeonol (Pae), a bioactive phenol, has anti‐tumor activity, but hydrophobicity, poor bioavailability, and instability limit its anti‐tumor effect. To overcome these problems, we constructed a nanoplatform of calcium phosphate (CA‐P) modified with polyacrylic acid (PAA) and loaded with Pae (Pae@CA‐P/PAA NPs). Pae@CA‐P/PAA NPs possess high drug‐loading levels and dual pH‐responsive properties. Because of the weak acidity of the tumor microenvironment (TME), the platform can passively target tumor sites. Compared with free Pae, Pae@CA‐P/PAA NPs effectively inhibited tumor cell growth and metastasis in vitro and in vivo. In conclusion, the nanoplatform is a promising strategy for the therapy of MBCs.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Blood Transfusion Third Xiangya Hospital Central South University Changsha 410013 Hunan P. R. China
Funding
National Natural Science Foundation of China
References (95)
Show source-provided references
1. [Internet] WHO: The Global Cancer Observatory. https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf ( March 2019).
2. 10.1038/485S49a10.1038/485S49a ↗
3. 10.21037/cco.2018.06.0910.21037/cco.2018.06.09 ↗
4. 10.1016/j.ajpath.2013.06.01210.1016/j.ajpath.2013.06.012 ↗
5.
6. 10.1038/nrc271310.1038/nrc2713 ↗
7. 10.1016/j.soncn.2015.02.00310.1016/j.soncn.2015.02.003 ↗
8. 10.1080/1120009X.2019.170741710.1080/1120009X.2019.1707417 ↗
9. 10.1016/j.intimp.2019.04.03310.1016/j.intimp.2019.04.033 ↗
10.
11. 10.3390/ijms15071176010.3390/ijms150711760 ↗
12. 10.3748/wjg.v16.i35.448310.3748/wjg.v16.i35.4483 ↗
13. 10.1016/j.ejphar.2008.02.01610.1016/j.ejphar.2008.02.016 ↗
14. 10.1002/iub.143510.1002/iub.1435 ↗
15.
16. 10.1097/CAD.0b013e3282f7f4eb10.1097/CAD.0b013e3282f7f4eb ↗
17. Fu J. · Int. J. Mol. Med. · 2018 · 42 · 1473
18. Li Q. · Oncol. Lett. · 2019 · 17 · 1761
19. 10.4062/biomolther.2013.10610.4062/biomolther.2013.106 ↗
20. 10.1111/j.1442-2050.2008.00840.x10.1111/j.1442-2050.2008.00840.x ↗
21. 10.1007/s13105-016-0537-x10.1007/s13105-016-0537-x ↗
22.
23. Zhang W. · Mol. Med. · 2015 · 12 · 1506
24. 10.3109/09553002.2013.82505810.3109/09553002.2013.825058 ↗
25. 10.1248/bpb.32.114210.1248/bpb.32.1142 ↗
26.
27. 10.1016/j.ijpharm.2010.09.03310.1016/j.ijpharm.2010.09.033 ↗
28. 10.1016/j.lfs.2020.11754410.1016/j.lfs.2020.117544 ↗
29.
30. 10.2147/IJN.S14393810.2147/IJN.S143938 ↗
31. 10.2217/nnm-2017-027710.2217/nnm-2017-0277 ↗
32. 10.12659/MSM.89448410.12659/MSM.894484 ↗
33. 10.3109/02652048.2014.91866410.3109/02652048.2014.918664 ↗
34. 10.2147/IJN.S5929010.2147/IJN.S59290 ↗
35. 10.1080/09205063.2016.126216110.1080/09205063.2016.1262161 ↗
36. 10.1016/j.ejps.2017.01.02810.1016/j.ejps.2017.01.028 ↗
37.
38. 10.1021/acsami.8b0195410.1021/acsami.8b01954 ↗
39. 10.1016/j.actbio.2017.11.01010.1016/j.actbio.2017.11.010 ↗
40. 10.1016/j.actbio.2011.11.01710.1016/j.actbio.2011.11.017 ↗
41.
42. 10.1080/14760584.2017.135573310.1080/14760584.2017.1355733 ↗
43. 10.3390/nano910138910.3390/nano9101389 ↗
44. 10.3390/nano911157010.3390/nano9111570 ↗
45. 10.1093/rb/rbw01010.1093/rb/rbw010 ↗
46. 10.1016/j.ejpb.2019.06.01310.1016/j.ejpb.2019.06.013 ↗
47.
48. 10.1021/acsami.5b0291210.1021/acsami.5b02912 ↗
49. 10.1080/03639045.2018.143846710.1080/03639045.2018.1438467 ↗
50. 10.1177/088532821663721110.1177/0885328216637211 ↗
51. 10.1016/j.colsurfb.2015.12.00710.1016/j.colsurfb.2015.12.007 ↗
52. 10.1021/la400347r10.1021/la400347r ↗
53. Smith K. · Nanomaterials · 2019 · 9
54. Karimi M. · Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. · 2016 · 8
55. Xu C. · Adv. Funct. Mater. · 2019 · 29
56.
57. 10.1021/mp800051m10.1021/mp800051m ↗
58. 10.1016/j.ejpb.2015.03.03310.1016/j.ejpb.2015.03.033 ↗
59. Xu C. · Adv. Funct. Mater. · 2019 · 29
60. 10.1016/j.jconrel.2005.05.00510.1016/j.jconrel.2005.05.005 ↗
61.
62. 10.1039/c2sm25135c10.1039/c2sm25135c ↗
63. 10.1080/03639045.2018.143846710.1080/03639045.2018.1438467 ↗
64.
65. 10.1016/j.biomaterials.2020.11976110.1016/j.biomaterials.2020.119761 ↗
66. 10.1038/nrd433310.1038/nrd4333 ↗
67.
68. 10.1021/bm301742m10.1021/bm301742m ↗
69. 10.1039/C5TB00264H10.1039/C5TB00264H ↗
70. 10.1038/srep0777410.1038/srep07774 ↗
71.
72. 10.1177/088532821663721110.1177/0885328216637211 ↗
73. 10.1016/j.msec.2017.03.22410.1016/j.msec.2017.03.224 ↗
74. 10.2147/IJN.S14393810.2147/IJN.S143938 ↗
75.
76. 10.1021/acsnano.6b0647710.1021/acsnano.6b06477 ↗
77. 10.1016/j.jconrel.2017.12.02610.1016/j.jconrel.2017.12.026 ↗
78. Lee S. H. · Clin. Cancer Res. · 2020
79. 10.1007/s10495-017-1424-910.1007/s10495-017-1424-9 ↗
80. 10.3390/cells902028210.3390/cells9020282 ↗
81. 10.1089/ars.2020.801910.1089/ars.2020.8019 ↗
82.
83. 10.1021/acsami.7b1678710.1021/acsami.7b16787 ↗
84. Xu C. · Adv. Funct. Mater. · 2019 · 29
85. 10.1007/s13402-018-0376-610.1007/s13402-018-0376-6 ↗
86.
87. 10.1016/j.eururo.2004.04.00110.1016/j.eururo.2004.04.001 ↗
88. 10.1016/j.semcancer.2015.03.00810.1016/j.semcancer.2015.03.008 ↗
89. 10.3892/ol.2016.552110.3892/ol.2016.5521 ↗
90. Mali A. V. · Asian Pac J Cancer Prev. · 2017 · 18 · 905
91.
92. 10.1002/(SICI)1097-0142(19961101)78:9<1881::AID-CNCR6>3.0.CO;2-I10.1002/(SICI)1097-0142(19961101)78:9<1881::AID-CNCR6>3.0.CO;2-I ↗
93. 10.1038/srep3212710.1038/srep32127 ↗
94. 10.1016/j.canlet.2017.10.02710.1016/j.canlet.2017.10.027 ↗
95. 10.1080/17425247.2016.120865010.1080/17425247.2016.1208650 ↗